The current standard treatment cures between 66% and 79% of patients with the most common type of hepatitis C, known as genotype 1, and who are undergoing the drugtherapyfor the first time, according to clinical data cited by the Food and Drug Administration.
Abdul-Jabbar also works as a paid spokesman for Novartis Pharmaceuticals, which makes Tasigna, the drugtherapy he takes to manage his CML. He says this role exposes him to a new fan base.